Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS
Miller, R. G., Block, G., Katz, J. S., Barohn, R. J., Gopalakrishnan, V., Cudkowicz, M., Zhang, J. R., McGrath, M. S., Ludington, E., Appel, S. H., Azhir, A.Volume:
2
Language:
english
Journal:
Neurology: Neuroimmunology & Neuroinflammation
DOI:
10.1212/nxi.0000000000000100
Date:
April, 2015
File:
PDF, 754 KB
english, 2015